• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).

作者信息

Yang Yunpeng, Zhou Hui, Zhang Li

机构信息

Medical Oncology Department, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People's Republic of China.

Medical Science and Strategy Oncology, Innovent Biologics, Inc., Shanghai, People's Republic of China.

出版信息

J Thorac Oncol. 2020 Dec;15(12):e191-e192. doi: 10.1016/j.jtho.2020.09.028.

DOI:10.1016/j.jtho.2020.09.028
PMID:33246599
Abstract
摘要

相似文献

1
Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).致编辑的信的回复：信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状非小细胞肺癌一线治疗的疗效和安全性：一项随机、双盲、3期研究（ORIENT-11）
J Thorac Oncol. 2020 Dec;15(12):e191-e192. doi: 10.1016/j.jtho.2020.09.028.
2
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).信迪利单抗联合培美曲塞和铂类化疗作为局部晚期或转移性非鳞状 NSCLC 患者一线治疗的有效性和安全性：一项随机、双盲、III 期研究（创新抗肿瘤 PD-1-11 研究）。
J Thorac Oncol. 2020 Oct;15(10):1636-1646. doi: 10.1016/j.jtho.2020.07.014. Epub 2020 Aug 8.
3
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study.ORIENT-11 研究中，信迪利单抗联合培美曲塞和铂类化疗作为局部晚期或转移性非鳞状 NSCLC 患者一线治疗的最终总生存数据。
Lung Cancer. 2022 Sep;171:56-60. doi: 10.1016/j.lungcan.2022.07.013. Epub 2022 Jul 19.
4
Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.比较信迪利单抗+培美曲塞联合铂类与单纯培美曲塞联合铂类作为中国非鳞状非小细胞肺癌患者一线治疗的成本效益。
Transl Cancer Res. 2023 Apr 28;12(4):928-938. doi: 10.21037/tcr-22-2030. Epub 2023 Mar 14.
5
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.3期ORIENT-11研究中，信迪利单抗联合培美曲塞和铂类作为局部晚期或转移性非鳞状非小细胞肺癌一线治疗的更新总生存数据及预测生物标志物
J Thorac Oncol. 2021 Dec;16(12):2109-2120. doi: 10.1016/j.jtho.2021.07.015. Epub 2021 Aug 3.
6
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).信迪利单抗联合铂类和吉西他滨作为晚期或转移性鳞状非小细胞肺癌的一线治疗：一项随机、双盲、3期试验（ORIENT-12）的结果
J Thorac Oncol. 2021 Sep;16(9):1501-1511. doi: 10.1016/j.jtho.2021.04.011. Epub 2021 May 25.
7
Generalizability of ORIENT-11 trial results to a US standard-of-care cohort with advanced non-small-cell lung cancer.ORIENT-11试验结果对美国晚期非小细胞肺癌标准治疗队列的可推广性。
Future Oncol. 2022 May;18(16):1963-1977. doi: 10.2217/fon-2022-0099. Epub 2022 Mar 31.
8
Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer.《墙上的另一块砖：信迪利单抗联合化疗治疗晚期肺癌》
J Thorac Oncol. 2020 Oct;15(10):1556-1558. doi: 10.1016/j.jtho.2020.08.013.
9
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.KEYNOTE-189 更新分析：帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌。
J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9.
10
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌患者的疗效报告（KEYNOTE-189）：一项多中心、双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2020 Mar;21(3):387-397. doi: 10.1016/S1470-2045(19)30801-0. Epub 2020 Feb 6.

引用本文的文献

1
Research progress of sintilimab in the treatment of cancer (Review).信迪利单抗治疗癌症的研究进展（综述）
Oncol Lett. 2025 Mar 21;29(5):240. doi: 10.3892/ol.2025.14986. eCollection 2025 May.
2
Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer.基线肿瘤血管灌注作为非小细胞肺癌免疫检查点治疗的一种非侵入性预测生物标志物。
BMJ Oncol. 2024 Aug 21;3(1):e000473. doi: 10.1136/bmjonc-2024-000473. eCollection 2024.
3
Pembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis.
帕博利珠单抗与信迪利单抗治疗晚期非小细胞肺癌患者的疗效对比：一项倾向评分匹配分析的回顾性多中心研究
Front Oncol. 2024 Dec 5;14:1422039. doi: 10.3389/fonc.2024.1422039. eCollection 2024.
4
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study.卡瑞利珠单抗联合卡铂和培美曲塞一线治疗晚期非鳞状非小细胞肺癌：CameL 随机 3 期研究的 5 年结果。
J Immunother Cancer. 2024 Nov 27;12(11):e009240. doi: 10.1136/jitc-2024-009240.
5
Safety and efficacy of sintilimab combination therapy for the treatment of 48 patients with advanced malignant tumors.信迪利单抗联合疗法治疗48例晚期恶性肿瘤患者的安全性和有效性
Transl Cancer Res. 2022 Jan;11(1):252-261. doi: 10.21037/tcr-22-54.
6
Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.非小细胞肺癌的治疗进展：聚焦于靶向治疗和免疫治疗的临床开发
MedComm (2020). 2021 Dec 14;2(4):692-729. doi: 10.1002/mco2.105. eCollection 2021 Dec.
7
Research progress in immune checkpoint inhibitors for lung cancer in China.中国肺癌免疫检查点抑制剂的研究进展
Ther Adv Med Oncol. 2021 Jul 20;13:17588359211029826. doi: 10.1177/17588359211029826. eCollection 2021.